about
N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome.Insulin resistance and hyperandrogenism have no substantive association with birth weight in adolescents with polycystic ovary syndrome.Pituitary-ovarian response to the gonadotrophin-releasing hormone-agonist test in anovulatory patients with polycystic ovary syndrome: predictive role of ovarian stroma.Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study.The growth hormone response to growth hormone-releasing hormone is blunted in polycystic ovary syndrome: relationship with obesity and hyperinsulinaemia.Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome.Obesity-related lipid profile and altered insulin incretion in adolescents with polycystic ovary syndrome.Failure of the homeostatic model assessment calculation score for detecting metabolic deterioration in young patients with polycystic ovary syndrome.A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio.Recombinant versus urinary follicle-stimulating hormone in the low-dose regimen in anovulatory patients with polycystic ovary syndrome: a safer and more effective treatment.Effect of luteal metoclopramide-induced hyperprolactinemia on pituitary and luteal responsiveness to gonadotropin-releasing hormone.Role of opioid tone in the pathophysiology of hyperinsulinemia and insulin resistance in polycystic ovarian disease.Opioid blockade effect on insulin beta-cells secretory patterns in polycystic ovary syndrome. Oral glucose load versus intravenous glucagon bolus.Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial.Influence of body mass on the hypothalamic-pituitary-adrenal-axis response to naloxone in patients with polycystic ovary syndrome.Somatostatin treatment reduces the exaggerated response of adrenocorticotropin hormone and cortisol to corticotropin-releasing hormone in polycystic ovary syndrome.Effect of pituitary adenylate cyclase-activating peptide on meiotic maturation in follicle-enclosed, cumulus-enclosed, and denuded rat oocytes.Very low dose of flutamide in the treatment of hyperandrogenism.The 312N variant of the luteinizing hormone/choriogonadotropin receptor gene (LHCGR) confers up to 2·7-fold increased risk of polycystic ovary syndrome in a Sardinian population.Ovulation induction in young girls with menometrorragia: a safe and effective treatment.The quantitative insulin sensitivity check index is not able to detect early metabolic alterations in young patients with polycystic ovarian syndrome.Effect of maternal carbohydrate metabolism on fetal growth.Endocrino-metabolic features in women with polycystic ovary syndrome during pregnancy.Hirsutism and hyperandrogenism associated with hyperreactio luteinalis in a singleton pregnancy: a case report.Ultrasound in polycystic ovary syndrome the measuring of ovarian stroma and relationship with circulating androgens: results of a multicentric studyIs the PCOS diagnosis solved by ESHRE/ASRM 2003 consensus or could it include ultrasound examination of the ovarian stroma?Acute insulin response to intravenous glucagon in polycystic ovary syndromeHeterogeneity in beta cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic ovary syndromeInfluence of chronic naltrexone treatment on growth hormone secretion in normal subjectsEffect of corticotropin-releasing factor on the pituitary-ovary axis in human luteal phaseMultiple serum marker assay in the diagnosis of endometriosisAssessment of the adrenal-ovarian contribution by short-term dexamethasone and ACTH tests in hyperandrogenized patientsEffect of Human Chorionic Gonadotropin Administration on Pituitary and Luteal Response to Gonadotropin-Releasing HormoneImportance of echographic and endocrine monitoring for the assessment of ovulation by follicle stimulating hormone in polycystic ovarian diseaseLH surge induction by GnRH agonist at the time of ovulationProgesterone and LH Variations after LH-RH Administration in the Luteal Phase of the Menstrual CycleThe impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome
P50
Q34132766-AF863105-BFC8-4A86-9DFB-4B56EC4709ABQ42472210-66875F1D-F8C1-46CB-B819-277B7678FF6FQ42500001-E419BE37-612D-4820-8391-74780EAF2B4AQ42509468-4F8CC8DD-A987-4086-805E-C59B844EAF75Q42514953-C056219B-E8CE-4CD7-BADF-783D548EB1A2Q42957595-C77A10AB-6421-4E03-AA8C-A776B82CA53CQ43088547-8F707436-6B57-42B6-81C0-D85C9759B170Q43612266-D076C7F0-E9F2-4F71-9A33-9F8265EA30BEQ43690288-CB83931B-3825-41F3-A53F-CCEA4A272635Q43820362-57E173E8-44D7-4785-9E6E-E9C826A3761FQ44328967-BEAB82C6-D285-4919-9C0B-BDF421B784A3Q44347952-C8A8D042-9601-49CC-A7F4-AE98CEB4E490Q44349046-4D587084-DBDB-4D2F-9615-5A6537742EBDQ46096612-B436D11C-F3DB-4F77-8A3B-ED4DA84D31EAQ48270820-3F1CACDA-988E-4E2B-9845-E734199D01BFQ48823731-CE9D4DA1-34D4-4221-9C29-1594DC1C99C6Q48950015-FD0D2B03-4759-4BB6-9259-D1A7EB2B59E0Q50134891-A5CC03F6-DD27-4BBD-9820-179F8E99D59FQ50962746-E1E4A9C7-CE30-4E02-A763-4E31E46002EBQ51175743-D9CF52E2-C9B6-48D6-ABE1-18F67E1A18B7Q51397854-72194578-0977-4031-91A0-1D9EE02F8EFAQ51569243-B5F3AFEF-AE04-4E70-A5F7-F931543DBAE2Q51570170-72340DB5-2491-4BF6-AD37-46B831A85797Q51750775-F8BC3741-B631-40B2-AC17-9657FF974470Q60717450-2389A9A3-CF99-43F1-BFEC-E2518CC7C059Q60717453-F87C4F03-893E-4D06-9BD3-C6214A24CB5CQ60717462-0B9F0865-CE0D-4C3F-B0F1-F51F2152194BQ60717465-8AB55618-537D-41E5-93C9-2FC4190F46B4Q60717468-AEAF7134-69E7-4A6F-AB8E-2C1F6C5031F1Q60717486-2F5135F8-C654-4551-94E7-3E8E7C7C7BD4Q60717534-EE6C923C-79B5-470D-931A-26E4CB6BEF1BQ60717539-5755769F-B428-4761-8F36-A44681987832Q60717563-E073DDBB-1600-4C1C-B86C-718EC5B51F36Q60717574-1241B2DA-2C07-4FBB-9816-D36224800EF4Q60717577-EC9C83CE-5DC6-4F53-B103-3C84C6273D4BQ60717591-BE621396-3C58-46A6-BD0D-60BF2C0270B0Q73047843-814F25CD-C0FE-4C36-9F00-FC6F2C5C8615
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Anna Maria Fulghesu
@ast
Anna Maria Fulghesu
@en
Anna Maria Fulghesu
@es
Anna Maria Fulghesu
@nl
type
label
Anna Maria Fulghesu
@ast
Anna Maria Fulghesu
@en
Anna Maria Fulghesu
@es
Anna Maria Fulghesu
@nl
prefLabel
Anna Maria Fulghesu
@ast
Anna Maria Fulghesu
@en
Anna Maria Fulghesu
@es
Anna Maria Fulghesu
@nl
P1053
J-9848-2016
P106
P1153
7004561764
P21
P31
P3829
P496
0000-0001-8116-3968